Two kidney-focused clinical trials testing either suppression of IL-6 with siltuximab (NCT02641522) in T1D patients or inhibition of IL-6R with tocilizumab in patients suffering from T2D and obesity (NCT01073826) were conducted but the results and conclusions are pending (140). Here, IL6 is linked to type 2 diabetes mellitus.